Comparative Pharmacology
Head-to-head clinical analysis: MINZOYA versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINZOYA versus ZOVIA 1 35E 28.
MINZOYA vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive